• Citer

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

par De Caluwé, Alex ;Buisseret, Laurence ;Poortmans, Philip;Van Gestel, Dirk ;Salgado, Roberto;Sotiriou, Christos ;Larsimont, Denis ;Paesmans, Marianne ;Ruscas-Craciun, Ligia Ioana ;Stylianos, Drisis;Vandekerckhove, Christophe;Reyal, Fabien;Isabelle, Veys;Eiger, Daniel;Piccart, Martine;Romano, Emanuela;Ignatiadis, Michail
Référence BMC cancer, 21, 1, page (899)
Publication Publié, 2021-08-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes. Pathological complete response (pCR) rate, however, is lower for luminal B BC in comparison to the triple negative (TNBC) and HER2+ subtypes. The addition of immune checkpoint blockade (ICB) to NACT has the potential to increase pCR rate but is hampered by the lower immunogenicity of luminal B BC. Novel strategies are needed to stimulate the immune response and increase the response rate to ICB in luminal B BC.